BEAT HeartBeam, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1779372 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.5%
TTM EPS YoY40.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-521.7%
ROA-335.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.3%
Debt / equity0.00x
Current ratio4.64x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-104.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.12M | $2.33M | $2.37M | $3.35M | $3.28M | $3.33M | $3.49M | $2.89M |
| SG&A expense | $1.34M | $2.76M | $2.35M | $1.96M | $2.01M | $1.71M | $2.01M | $2.06M |
| Operating income | -$3.46M | -$5.09M | -$4.72M | -$5.31M | -$5.29M | -$5.04M | -$5.50M | -$4.94M |
| Pretax income | -$3.01M | -$5.04M | -$4.70M | -$5.30M | -$5.25M | -$4.97M | -$5.48M | -$4.91M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.01M | -$5.04M | -$4.70M | -$5.30M | -$5.25M | -$4.97M | -$5.48M | -$4.91M |
| EBITDA | -$3.39M | -$5.04M | -$4.69M | -$5.29M | -$5.28M | -$5.03M | -$5.50M | -$4.94M |
| EPS (basic) | -0.05 | -0.10 | -0.12 | — | -0.15 | -0.15 | -0.18 | — |
| EPS (diluted) | -0.05 | -0.10 | -0.12 | — | -0.15 | -0.15 | -0.18 | — |
| Weighted avg. shares (diluted) | 57.20M | 52.77M | 40.59M | — | 34.40M | 33.83M | 30.38M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $6.07M | $8.72M | $2.04M | $4.38M | $1.86M | $3.26M | $4.39M | $2.43M |
| Inventory | $114,000 | $110,000 | $133,000 | $103,000 | — | — | — | $0 |
| Current assets | $6.30M | $9.00M | $2.44M | $4.68M | $2.13M | $5.36M | $8.61M | $2.77M |
| PP&E, net | $1.52M | $1.58M | $1.44M | $1.10M | $694,000 | $564,000 | $443,000 | $450,000 |
| Total assets | $7.87M | $10.64M | $3.93M | $5.84M | $2.88M | $5.98M | $9.11M | $3.28M |
| Current liabilities | $1.36M | $2.46M | $3.29M | $3.24M | $2.47M | $1.80M | $1.58M | $1.62M |
| Total liabilities | $1.36M | $2.46M | $3.29M | $3.24M | $2.47M | $1.80M | $1.58M | $1.62M |
| Shareholders' equity | $6.51M | $8.18M | $635,000 | $2.60M | $406,000 | $4.18M | $7.53M | $1.65M |
| Shares outstanding | 57.51M | 56.35M | 41.13M | 40.12M | 34.34M | 34.02M | 33.73M | 26.96M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.59M | -$3.34M | -$3.61M | -$2.91M | -$3.16M | -$3.44M | -$4.48M | -$4.15M |
| Capital expenditure | $69,000 | $249,000 | $246,000 | $416,000 | $82,000 | $102,000 | $0 | $0 |
| Free cash flow | -$2.66M | -$3.59M | -$3.86M | -$3.32M | -$3.24M | -$3.55M | -$4.48M | -$4.15M |
| Investing cash flow | -$69,000 | -$249,000 | -$246,000 | -$416,000 | $1.72M | $1.86M | -$3.76M | $0 |
| Financing cash flow | $0 | $10.28M | $1.51M | $5.85M | $45,000 | $450,000 | $10.25M | $761,000 |
| Depreciation & amortization | $69,000 | $57,000 | $24,000 | $17,000 | $8,000 | $8,000 | $7,000 | $7,000 |
| Stock-based compensation | $937.00M | $1.70B | $1.22M | $1.43M | $1.43B | $1.18B | $1.11M | $999,000 |
Free plan shows the latest 8 periods; Pro shows all 25 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.